EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct remission immune architectures under rituximab and azathioprine in AQP4-IgG-positive neuromyelitis optica spectrum disorder

Wangyong Shin, Bohwan Yoon, Hyo Jae Kim, Dayoung Seo, Inhye Jang, Jihong Ryu, Lynkyung Choi, Jinhee Kim, Hyunjin Kim, Young-Min Lim, Hyung-Seung Jin, Eun-Jae Lee

Frontiers in Immunology · 08.05.2026 · 17

DOI: 10.3389/fimmu.2026.1834992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 08.05.2026. Verfasst von Wangyong Shin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine., Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Rituximab, Azathioprine, Neuromyelitis Optica, Immunoglobulin G. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Maintenance immunotherapy is effective in AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD), but how mechanistically distinct maintenance therapies organize the remission immune landscape and its relationship to neurological disability remains poorly defined.

Methods

We performed integrated multiparameter flow cytometry and plasma cytokine profiling in serial remission samples (up to three per patient) from 28 patients receiving rituximab (RTX, n = 14) or azathioprine (AZA, n = 14). Between-treatment comparisons, within-treatment coupling analyses, and disability-associated immune analyses were conducted using age-adjusted patient-clustered regression models with prespecified false discovery rate control.

Results

RTX showed clear target engagement, characterized by profound B-cell depletion, gradual post-infusion reconstitution, and sustained reduction of natural killer T (NKT)-like cells. Beyond lineage depletion, RTX was associated with regulatory remodeling, including a memory-skewed regulatory T (Treg) phenotype and a lower effector-to-regulatory balance. In B-detectable RTX samples, the reconstituting B-cell compartment was transitional/naive-skewed with marked suppression of memory B cells. Although remission-phase cytokines were broadly low, interferon gamma-induced protein 10/CXC motif chemokine ligand 10 (IP-10/CXCL10) remained selectively elevated under RTX. Importantly, remission immune architecture differed by therapy: AZA showed a T cell immunoreceptor with Ig and ITIM domains (TIGIT)-linked regulatory disability axis, whereas RTX showed disability coupling to soluble inflammatory mediators, particularly interleukin-6 (IL-6) and IP-10.

Conclusion

Mechanistically distinct maintenance therapies impose divergent remission immune architectures in NMOSD. These findings support a treatment-aware framework for biomarker interpretation and suggest that remission monitoring should consider therapy-specific immune networks rather than isolated immune markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabAzathioprineNeuromyelitis OpticaImmunoglobulin GAquaporin 4Immunosuppressive AgentsImmunologic FactorsHumansFemaleMaleAdultMiddle AgedCytokinesAutoantibodiesRemission InductionB-LymphocytesChemokine CXCL10

Stichwörter der Autor:innen

IP-10/CXCL10NMOSDTIGITazathioprineremissionrituximab

Substanzen

RituximabAzathioprineImmunoglobulin GAquaporin 4CytokinesAQP4 protein, humanAutoantibodiesImmunosuppressive AgentsImmunologic FactorsChemokine CXCL10

Autor:innen und Institutionen

  • Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine., Seoul, Republic of Korea.
  • Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Shin, W., Yoon, B., Kim, H. J., Seo, D., Jang, I., Ryu, J., Choi, L., Kim, J., Kim, H., Lim, Y. M., Jin, H. S., & Lee, E. J. (2026). Distinct remission immune architectures under rituximab and azathioprine in AQP4-IgG-positive neuromyelitis optica spectrum disorder. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1834992

Vancouver

Shin W, Yoon B, Kim HJ, Seo D, Jang I, Ryu J, et al. Distinct remission immune architectures under rituximab and azathioprine in AQP4-IgG-positive neuromyelitis optica spectrum disorder. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1834992

BibTeX
@article{Shin2026,
  author = {Shin, Wangyong and Yoon, Bohwan and Kim, Hyo Jae and Seo, Dayoung and Jang, Inhye and Ryu, Jihong and Choi, Lynkyung and Kim, Jinhee and Kim, Hyunjin and Lim, Young-Min and Jin, Hyung-Seung and Lee, Eun-Jae},
  title = {Distinct remission immune architectures under rituximab and azathioprine in AQP4-IgG-positive neuromyelitis optica spectrum disorder},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1834992}
}
Kostenlos starten →